Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
Carmen Escuriola EttingshausenOlga KatsarouBarbara Faganel KotnikAnnie Borel DerlonRudolf SchwarzPaula F YpmaIrina MatytsinaSohan DeyRoger E G SchutgensPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)
Turoctocog alfa was safe and efficacious for haemophilia A treatment in routine clinical practice.